A 14 Week, Randomized, Double-blind, Multi-center, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Elderly Patients With Essential Hypertension
A 14 Week, Randomized, Double-blind, Multi-center, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Elderly Patients With Essential Hypertension
The purpose of this study is to access the efficacy and safety of LCZ696 compared to olmesartan in elderly Asian patients for the treatment of hypertension.
Inclusion Criteria:
Exclusion criteria:
Chikushi-gun, Fukuoka 811-1244, Japan
Hiki-Gun, Saitama 355-0328, Japan
Edogawa-ku, Tokyo 133-0061, Japan
Edogawa-ku, Tokyo 134-0084, Japan
Meguro-ku, Tokyo 152-0031, Japan
Minato-ku, Tokyo 105-7390, Japan
Minato-ku, Tokyo 108-0075, Japan
Shibuya-ku, Tokyo 150-0002, Japan
Shinagawa-ku, Tokyo 141-0032, Japan
Toshima-ku, Tokyo 171-0021, Japan
Koyang, Kyunggi 410-719, South Korea